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Abstract: Metronidazole, a common antibacterial drug, was incorporated into a 
hydrophilic polymer matrix composed of chitosan xanthan gum mixture. Hydrogel 
formation of this binary chitosan-xanthan gum combination was tested for its ability to 
control the release of metronidazole as a drug model. This preparation (MZ-CR) was 
characterized by in vitro, ex vivo bioadhesion and in vivo bioavailability study. For 
comparison purposes a commercial extended release formulation of metronidazole (CMZ) 
was used as a reference. The in vitro drug-release profiles of metronidazole preparation 
and CMZ were similar in 0.1 M HCl and phosphate buffer pH 6.8. Moreover, 
metronidazole preparation and CMZ showed a similar detachment force to sheep stomach 
mucosa, while the bioadhesion of the metronidazole preparation was higher three times 
than CMZ to sheep duodenum. The results of in vivo study indicated that the absorption of 
metronidazole from the preparation was faster than that of CMZ. Also, MZ-CR leads to 
higher metronidazole Cmax and AUC relative to that of the CMZ. This increase in 
bioavailability might be explained by the bioadhesion of the preparation at the upper part 
of the small intestine that could result in an increase in the overall intestinal transit time. As 
a conclusion, formulating chitosan-xanthan gum mixture as a hydrophilic polymer matrix 
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resulted in a superior pharmacokinetic parameters translated by better rate and extent of 
absorption of metronidazole.  
Keywords: metronidazole; chitosan; xanthan gum; bioadhesion; bioavailability 
 
1. Introduction 
 
The simplest technique to prepare a controlled release matrix system is through direct compression 
of a single hydrophilic polymer with the drug substance. A wide variety of controlled release matrices 
have been developed. These include single component hydrophilic polymers such as hydroxypropyl 
methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), sodium alginate, chitosan and xanthan gum 
[1–4]. However, depending on the system modifications, various drug release rates and patterns can be 
accomplished. The swelling mechanisms and kinetics of drug release from these systems are highly 
complex and therefore difficult to understand, as evidenced in previous publications [5–7]. 
It is evident that using single hydrophilic component has its shortcomings. Those for example, 
when polymer-retarding activity is only working at the outer layers of the tablet, with minimum 
hindering effect on drug release. Other shortcoming is the fluctuation of drug release at various time 
intervals [8]. Such drawbacks dictate the introduction of a second polymer modifying the drug 
dissolution from the first polymer. This concept was previously applied where a synergistic effect 
between xanthan and locust bean gums caused a more controllable drug release of a variety of drugs. 
This system is a mixture of natural hydrophilic polymer combination which gels in aqueous 
environment forming tight gel allowing precise predictable release patterns. Such system is 
commercialized under trademark TIMERx
® where nifedipine and oxybutynin are marketed in 
European markets as controlled release dosage forms [9–11]. 
Another interesting combination of hydrophilic polymers includes the use of a binary system 
composed of chitosan and xanthan gum. Chitosan is the linear cationic β(1-4) polysaccharide obtained 
by partial random deacetylation of chitin [4,12–14]. Xanthan gum is a heteropolysaccharide chain 
consists of two β-D-glucose units linked through the 1 and 4 positions. The side chain consists of two 
mannose and one glucuronic acid, so the chain consists of repeating modules of five sugar units. The 
side chain is linked to every other glucose of the backbone at the 3 position. About half of the terminal 
mannose units have a pyruvic acid group linked as a ketal to its 4 and 6 positions. The other mannose 
unit has an acetyl group at the 6 positions [1,15,16]. Xanthan gum, as a branched anionic 
polysaccharide, and chitosan form polyelectrolyte complexes that may function as a release-retarding 
barrier. The combination between xanthan gum and chitosan has been examined by different   
authors [17,18]. 
The residence time at different gastrointestinal sites represents a serious limitation that precludes 
the dosage form from optimization [19]. Hence, several attempts have been recently undertaken 
aiming at the prolongation of the gastric residence times. These include the use of floating drug 
delivery systems and polymeric bioadhesive systems, where some hydrophilic polymers has th]e 
property to adhere to biological membranes such as chitosan and xanthan gum [20–22]. Although the Mar. Drugs 2010, 8 
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optimal controlled release ratio of binary mixture of chitosan and xanthan gum (i.e., 1:1 w/w) was 
described previously [23–25] the bioadhesion of the binary mixture has not been   
systematically explored. 
Consequently in this study, the assessment of bioadhesion of this controlled release matrix 
composed of binary mixture of chitosan-xanthan and its effect on metronidazole release in vitro and in 
vivo are described and compared with a commercially available metronidazole controlled release 
(CMZ) tablet based on a single retarding polymer (Leading Brand®).  
 
2. Results and Discussion 
 
Formulation of metronidazole controlled release tablets was based on the drug mixed with a 1:1 
mass ratio between chitosan and xanthan gum. This ratio was based upon its suitability of use. At this 
ratio, the maximum interaction between chitosan and xanthan gum takes place, in addition, a good 
compressible (or flowable) and a highly compactable powder characteristics are attained at this ratio 
[25]. Therefore, industrial processing of this formulation is not expected to become a constraint when 
scaling-up is desired. 
Hardness and friability were over 110 N and less than 0.5% for the uncoated MZ-CR tablets, 
respectively. Assay of metronidazole tablets was carried out in accordance to USP monograph. 
Metronidazole assay in the reference and test tablets were complying with USP monograph and found 
to be 101.65% and 100.34% for CMZ and MZ-CR, respectively. 
 
2.1. In vitro release study 
 
The in vitro dissolution profiles of MZ-CR and CMZ in 0.1 M HCl and in 0.1 M HCl/phosphate 
buffer, pH 6.8, are presented in Figures 1 and 2, respectively.  
A power law is used to describe drug release from polymeric system (1):  
Q = kt
n        ( 1 )  
where Q is the percentage of drug release; k is a constant incorporating structural and geometric 
characteristics of the device, and n is the release exponent, which is indicative of the mechanism of 
drug release. 
Table 1 represents k,  n and the correlation coefficient of MZ-CR and CMZ in 0.1 M HCl of   
Figure 1 and in phosphate buffer pH 6.8 phase of Figure 2, according to the power law. As shown in 
Table 1, the drug release from the polymeric matrix in 0.1 M HCl seemed to follow anomalous 
transport in the case of CMZ and indicate a swelling-controlled drug release for MZ-CR. On the other 
hand, anomalous diffusion seems to be the release mechanism of MZ-CR and CMZ in phosphate 
buffer. Therefore, the mechanism of release, in the case of MZ-CR has changed from being swelling-
controlled to be anomalous diffusion. This could be explained by considering hydrogel formation. 
However, the rate constant (k) of MZ-CR was higher than that of CMZ in 0.1 M HCl. The release 
pattern of MZ-CR appeared to be almost similar to that of CMZ in 0.1 M HCl where the f2 factor was 
58.04%. Such similarity could be explained from the lower n value of CMZ than that of MZ-CR and Mar. Drugs 2010, 8 
 
 
1719
the lower k value of CMZ than that of MZ-CR. While, in phosphate buffer the release kinetics were 
almost similar for MZ-CR and CMZ, where the f2 factor for the in vitro data was 79.96%. 
Consequently, the two preparations have similar in vitro release behavior. 
 
Figure 1. In vitro dissolution profile of MZ-CR and CMZ in a USP paddle apparatus using 
a dissolution medium of 900 mL of 0.1 M HCl for 2 hrs then USP phosphate Buffer,  
pH 6.8 for the rest period, 50 rpm and at 37 
oC. 
 
 
Figure 2. In vitro dissolution profile of MZ-CR and CMZ in USP paddle apparatus using a 
dissolution medium of 900 mL of 0.1 M HCl, 50 rpm and at 37 
oC.  
.  
 
 Mar. Drugs 2010, 8 
 
 
1720
Table 1. Summary of power equation (Equation 1) components k, n and the correlation 
coefficient of MZ-CR and CMZ. 
  MZ-CR CMZ 
 HCl 
K 29.48  25.37 
N 0.8005  0.5789 
r
2  0.992 0.988 
  Phosphate Buffer, pH = 6.8 
K 6.27  5.52 
N 0.6654  0.7679 
r
2  0.997 0.997 
 
2.1.1. Bioadhesion  
 
The results of bioadhesion test performed on sheep stomach and duodenum for XG, CS, PEG, CT, 
MZ-CR and CMZ are presented in Figure 3. The bioadhesion of each component in the MZ-CR 
formulation was evaluated individually in order to elucidate the contribution of each component to 
bioadhesion. As shown in Figure 3, XG had the highest weight of detachment compared to that of CS 
and PEG 10,000. Moreover, the bioadhesion force of XG, CS, PEG and CMZ was higher in stomach 
than that in the duodenum, while the bioadhesion of CT and the MZ-CR formulation was almost the 
same in both the stomach and duodenum.  
A comparison between MZ-CR and CMZ showed that both had a similar bioadhesion to stomach, 
while MZ-CR exerted a higher adhesion power to duodenum than CMZ. This could be explained by 
the formation of a hydrogel at media pH of the duodenum.  
However, for prediction purposes, the weight of detachment of CT was calculated theoretically 
according to additivity rule. The weights of detachment of CT theoretically and experimentally are 
shown in Figure 4. The results suggest that bioadhesion does not follow the simple additivity rule. 
Bioadhesion of the tablet with mucus tissue could be dependent on polymer concentration and/or 
availability of the surface. The polymer swellability is not the same for all polymeric components. 
Thus, their distribution and availability on the surface of the tablet might be modified once the tablet 
has been wetted. Accordingly, adhesion to the mucosa surface will be modified and the additivity rule 
will not be valid any more. This difference in bioadhesion might modify the gut transit time and may 
affect drug bioavailability as reported in such systems [26]. Mar. Drugs 2010, 8 
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Figure 3. Weight of detachment per area (g/cm
2) against each component in the formula of 
XG, CS, PEG, CT, MZ-CR, and CMZ. 
 
Figure 4. The calculated (theoretical) and the experimental values of weight of detachment 
per area (g/cm
2) of a drug free tablet CT in stomach and duodenum. 
 
 
2.2. In vivo study 
 
As shown in the summary table of the main pharmacokinetic metrics (Table 2), the absorption of 
metronidazole from the test product (MZ-CR) was faster than that of CMZ with a maximum plasma 
level attained at 4.37 and 6.14 hours, respectively. This relative faster absorption has resulted in 
significantly higher metronidazole maximum plasma for the test product (9.08 g/mL) relative to that Mar. Drugs 2010, 8 
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of the reference product (4.03 g/mL). Trough levels at 24 hours post dose for both products after a 
single dose were almost identical and stand approximately at 1.8 g/mL. 
 
Table 2. Summary of the main pharmacokinetic parameters for the test and reference 
products directly estimated from the plasma concentration-time data.  
  Tmax C max T 0.5 AUC0-t AUC0-∞ 
Vol.  No.  T R T R T  R  T  R  T  R 
1  5.00 4.00 7.96 2.62  18.74 151.10 91.74 43.81  123.65 372.97 
2  5.50 10.00 7.08  3.16 20.64 44.15  81.53  52.71 122.63 119.59 
3  3.00  6.50 11.93 4.75 16.73 23.84 107.45 70.89 132.07 115.95 
4  4.00 5.00 9.28 3.25  27.42 50.73  121.67 63.73  214.62 213.04 
5  5.00 6.00 8.98 8.24  23.91 27.09  108.18 112.73  179.23 212.39 
6  4.00 5.00 9.32 3.93  22.61 31.77 97.77 63.60  147.04 125.93 
7  5.00 8.00 9.11 3.27  27.89 93.25  103.72 57.19  185.00 332.97 
8  4.00 6.50 9.75 5.19  26.45 59.22  124.67 71.48  213.97 276.53 
G_Mean 4.37 6.14 9.08 4.03  22.71 49.88  103.70 64.67  160.86 201.46 
STDEV  0.82 1.90 1.41 1.81 4.13 42.98 14.44 20.66 38.50  99.44 
SEM  0.29 0.67 0.50 0.64 1.46 15.20  5.11  7.30  13.61  35.16 
%  CV  18.50 29.87 15.33 42.09 17.91 71.46  13.81  30.82  23.36  44.96 
 
The faster absorption and the higher plasma concentration of metronidazole released from MZ-CR 
may be attributed to the adhesion characteristics of the hydrogel matrix causing a delay in its transit 
away from the upper part of the small intestine were absorption is anticipated to be optimum [27]. 
Furthermore, a significant difference in the area under the plasma concentration-time for MZ-CR and 
CMZ is illustrated. However, extrapolating the data to infinity resulted in a larger area under the curve 
for the CMZ compared to MZ-CR. 
This situation clearly suggests that comparisons based on values involving extrapolation must be 
undertaken with caution and would prove to be misleading and may produce unwarranted impact on 
the error term associated with the parameter being examined. Such impact is depicted by 90% exact 
confidence region where the area under the plasma concentration-time curve from time zero to infinity 
has been increased by more than five-fold in comparison to the area to the last sampling point. This 
situation could be rectified by the elimination of the most outlying subject. The coefficient of variation 
of CMZ was clearly much higher for all pharmacokinetic parameters in comparison with MZ-CR. This 
suggests that CMZ resulted in a higher variability in plasma concentration time profiles. Nevertheless, 
MZ-CR preparation gave a more reliable plasma concentration data as shown in Figure 5. 
The mean elimination half-life of MZ-CR and CMZ as estimated from the plasma concentration-
time profiles are given at 22.7 and 49.9 hours, respectively. Since such findings have a significant 
effect on the accumulation characteristics of the formulation upon multiple dosing, a simulation study 
for such situation has been undertaken. The actual pharmacokinetic metrics estimated from the 
empirical data were used in the simulation shown in Figure 6. Multiple dosing usually results in 
accumulation of metronidazole until a steady state is attained. The time needed to reach a steady state Mar. Drugs 2010, 8 
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was around four days for MZ-CR, while in case of CMZ it needs about 10 days to reach the steady 
state. Such impact could be better appreciated once the therapeutic index of metronidazole is defined. 
 
Figure 5. Mean plasma conc.time profiles following the administration of 750 mg 
metronidazole tablets for eight subjects (mean ± SEM). 
 
 
Figure 6. Accumulation of metronidazole in the plasma upon multiple dosing of 750 mg 
metronidazole every day for MZ-CR, CMZ and metronidazole immediate release 
(simulated). 
 
 
Metronidazole is a drug that is used to treat infections caused by microbes. The clinical or 
pharmacological difference between MZ-CR and CMZ will be discussed in terms of metronidazole 
antimicrobial efficacy.  
Metronidazole exhibits in vitro minimal inhibitory concentrations (MICs) of 8 μg/mL or less 
against most (≥90%) strains of the Gram-negative anaerobes such as the Bacteroides fragilis group (B. 
caccae, B. uniformis) and Prevotella  species (P. bivia, P. buccae, P. disiens) microorganisms. 
However, the problem of metronidazole, as with most antimicrobials, is the appearance of drug-Mar. Drugs 2010, 8 
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resistant strains. Many microbes have developed resistance to metronidazole, especially some strains 
of Helicobacter. Two H. felis strains showed a MIC of 16 μg/mL for metronidazole, suggesting 
acquired resistance to this antimicrobial agent [28,29]. 
The reason for the appearance of drug-resistant strains comes from incomplete eradication of 
bacterial infection by the antimicrobial therapy and/or the larger exposure time of bacterial pathogens 
to sub-inhibitory concentrations, which could lead to the selection of resistant strains of bacterial 
populations [30–32]. 
The antimicrobial efficacy is particularly dependent on the time that free plasma concentrations of 
the drug exceeding the minimum inhibitory concentration (MIC) for the target pathogen (T > MIC) 
[33]. It is well known that the increase in pathogen MICs (drug-resistant pathogens) can be overcome 
with increased unit doses, dose frequency and/or improved pharmacokinetics to maintain adequate  
T > MIC. Thus, in order to increase efficacy, there is a need to increase the total amount of drug given 
per dose [34]. 
This reveals the importance for the use of sustained release preparation that provides a constant 
level of antimicrobial drug above the MIC all over the therapeutic period. The achievement of high 
plasma level of antimicrobials may prevent the development of drug-resistant bacterial strains. This 
has been achieved by the increase in extent of drug absorption, and hence bioavailability, of MZ-CR in 
comparison with CMZ. The plasma concentration of metronidazole provided by MZ-CR was higher 
than CMZ all over their plasma concentration time profile for the entire period of 24 hrs, as shown in 
Figure 5. This means that microbes will be exposed to higher concentration of metronidazole for the 
entire period of 24 hr in MZ-CR preparation when compared to CMZ. This is important in order to 
maximize the antimicrobial agents efficacy against the development of resistant strains through the use 
of optimized kinetic profiles [35,36]. 
As conclusion, this study reveals the importance of carrying out ex vivo bioadhesion study for the 
evaluation of a newly developed controlled release matrix system in concurrent with in vitro release 
tests before conducting in vivo studies. Although the in vitro drug release studies indicated similarity in 
the release, the in vivo study showed a large difference in plasma concentration time profiles. On the 
other hand, the study indicates higher Cmax of MZ-CR compared to CMZ due to the synergistic 
bioadhesion of the binary mixture of chitosan-xanthan gum on the upper part of the intestine. 
 
3. Experimental 
 
3.1. Materials 
 
Pharmaceutical grade chitosan (CS) with a viscosity of 16.80 mPas (0.5% (w/v) in 0.1M HCl), 
having a 93% degree of deacetylation and average particle size of 170 μm, was purchased from Hong 
Ju, China. Food and pharmaceutical grade xanthan gum (XG) with a viscosity of 40.7 mPas (0.5% 
(w/v) in water) and average particle size of 106.7 μm, was purchased from Jungbanzlauer, Germany. 
Polyethylene Glycol (PEG) having molecular weight of 10 kDa was obtained from Sigma-Aldrich, 
Germany. Metronidazole (MZ) was purchased from Lution-Hong Gou, China. Mar. Drugs 2010, 8 
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CMZ coated tablets were used as a commercially available metronidazole reference product purchased 
from the USA market. CMZ tablets contain 750 mg of metronidazole USP. Inactive ingredients 
include hypromellose, lactose, magnesium stearate, polyethylene glycol, poly(methyl)acrylic acid ester 
copolymers, polysorbate 80, silicon dioxide, simethicone emulsion, talc, titanium dioxide, FD&C Blue 
No. 2 Aluminum Lake. 
 
3.2. Methods 
 
3.2.1. Preparation of MZ controlled release preparation (MZ-CR) 
 
A powder mixture of 100 g containing 69.3 g metronidazole, 13.8 g polyethylene glycol and 8.45 g 
xanthan gum was granulated using 1% (w/w) solution of xanthan gum. The granulated mixture was 
passed on US mesh #4 sieve and dried in an oven at 45 ºC for 3 hours. Finally, the dry powder was 
sieved on a US mesh #22 sieve and mixed with 8.45 g of chitosan. The prepared granules were 
compressed into tablets containing 750 mg metronidazole using a single punch machine (Manesty, 
England). Punches with oblong shape (19 mm × 9.5 mm) were used.  
 
3.2.2. In vitro dissolution test  
 
The in vitro release was performed using USP method II (paddle). The dissolution media in the first 
set of experiments was 0.1M HCl for six hours, while in the second set 0.1M HCl was replaced with 
phosphate buffer of pH 6.8 after 2 hours. The volume of dissolution media in each vessel was 900 mL 
and the temperature was maintained at 37 ± 0.5°C during the study. The paddle speed was adjusted to 
50 rpm. Samples of 5mL were withdrawn at different time intervals (1, 2, 3, 4, 6, 8, 10, and 12 hours). 
Each withdrawn sample was replaced by 5 mL at each time of dissolution media. The percentage drug 
release was determined using of UV-spectrophotometer where λmax was 276 nm in HCl and 322 nm in 
phosphate buffer respectively. A calibration curve was constructed and the concentration of 
metronidazole was read from that curve.  
 
3.2.3. Similarity factor  
 
The dissolution profiles for MZ-CR and CMZ in different media were compared using Similarity 
factor (f2) suggested by FDA (1995) [37] and is described by Equation 2. Dissolution profiles of the 
reference and test products would be considered similar when f2 is larger than 50: 
f2 = 50 × log ([1 + Q/n]
0.5  ×  100)       (2) 
where Q equals the sum of squared differences between the percent released from the test and 
reference formulations at the sampling intervals (t = 1,…,n), where n refers to the number of   
sampling points. 
 Mar. Drugs 2010, 8 
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3.2.4. In vitro bioadhesion test 
 
Bioadhesion was evaluated through the measure of maximum load necessary for the detachment of 
a tablet of defined composition from the surface of a sample of a biological tissue. The bioadhesion of 
tablets to sheep stomach and duodenum was measured using a modified two-arm balance method 
described by Parodi et al., in 1996 [38]. The tablets were sandwiched between freshly prepared tissues 
of a sheep stomach or duodenum purchased from a local slaughterhouse. The tissues were cut into 
strips (2 × 3 cm) cleaned and wetted with normal saline. The upper tissue strip was placed under a 
movable plastic platform, while the lower strip was placed on a fixed stage. 
Tablets were initially soaked in 0.1 M HCl for five minutes if stomach parts were used or in 0.1 M 
HCl and then placed in phosphate buffer (pH 6.8) for another five minute if duodenum parts were 
used. A preload of 10 g was placed above the sandwiched tablet for five minutes to establish adhesion. 
The preload was removed and water was pumped to a plastic container by a peristaltic pump at a rate 
of 10mL/min. The addition was stopped as soon as the detachment of the tablet from the mucosa. The 
weight of detachment was then calculated as the peak weight of the added water required for the 
detachment of the upper biological tissue from the tablet surface per area (calculated in g/cm
2) was 
used as indicator for tablet bioadhesion. 
This test was performed on drug-free compacts of XG, CS, PEG, CT (control tablets containing all 
additives), while MZ-CR and CMZ tablets were used as metronidazole containing compacts. 
 
3.2.5. In vivo assessment of MZ controlled release dosage form 
 
A pilot study was undertaken to measure the rate and extent of absorption of 750 mg metronidazole 
in Test (MZ-CR controlled release preparation) and in CMZ. The in vivo study was approved by the 
Ethical Committee of the Ibn Al-Haytham Hospital in Amman, Jordan (where the study was 
conducted). Volunteers’ consents were obtained in concordance with the Declaration of Helsinki and 
Good Clinical Practice was followed throughout the study. 
The study was conducted in accordance with an open, randomized, single-dose, two-treatments, 
two-periods, crossover design under fasting conditions. The hospitalization period was a total 24 hours 
including 12 hours before dosing, and 12 hours after dosing in each period. The dosing periods were 
separated by a washout period of sufficient length (7 days) which far exceeds ten elimination half-lives 
of the drug. The study consisted of eight healthy, 30–35 year old male participants. The metronidazole 
products were administered in the morning (at 8:00am) with 240 mL of water following a 12-hour 
fasting. A total of 20 blood samples were collected according the following sample collection 
schedule: 0 (20 mL pre-dosing) and 10 mL at 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7,8, 10, 12, and  
24 hours after dosing. 
All samples were collected in EDTA blood tubes, and centrifuged at 3,000 rpm for 4 minutes; 
plasma samples were transferred to screw top polypropylene tubes. These were capped and 
immediately stored at –30 ± 5 
oC until analysis. 
 Mar. Drugs 2010, 8 
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3.2.6. Determination of metronidazole in plasma 
 
A standard curve of metronidazole was prepared in plasma in the range of 0.10–15.0 g/mL, 
sample preparation consisted of the addition of 0.2 mL of perchloric acid (10%) and 0.2 mL of   
100 g/mL of the internal standard (hydrochlorothiazide) and 50 l of 4 M sodium acetate to 0.2 mL 
of plasma in eppendorf tubes, and vortexed for 1 minute. The supernatant was centrifuged for   
10 minutes at 4,000 rpm and 50 L sample was injected onto Hypersil phenyl column using 85% of 
potassium dihydrogen phosphate and 15% acetonitrile, the final pH was adjusted to 3.6. Metronidazole 
and the internal standard were separed from endogenous substances and the retention time was 3.0 to 
4.0 minutes for hydrochlorothiazide at flow rate of 1.0 mL/minute. The lower limit of detection was 
0.10 g/mL. 
 
3.2.7. Pharmacokinetic analysis 
 
The pharmacokinetic parameters were directly estimated from the plasma concentration-time data 
profiles. The elimination half-life (t1/2), expressed as ln(2)/Ke (Ke is the elimination rate constant), was 
estimated from the slope of the terminal segment of the plasma profile. The area from time zero to the 
last sampling point was also determined based on trapezoidal rule (AUC0-tlast).  
 
3.2.7.1. Evaluation of bioavailability 
 
Relative bioavailability was determined based on the test to reference ratio (T/R) of geometric 
means of the main pharmacokinetic metrics of interest such as AUC0-t and Cmax. 
 
3.2.7.2. Statistical considerations 
 
The statistical treatment of data was based on a statistical model suited for a K-sequence and J-
period crossover design: 
Yijk = µ + Gk + Sik +Pj +F(j.k) + C(i – 1, K) + eijk       ( 3 )  
where i = 1,...,nk; µ = the overall sample mean; J = 1,...,J; k= 1,...K; G, P and F are the respective fixed 
sequence (k), period (P) and formulation (F) effects; C(i – 1, K) is the fixed first order carryover effect (C) 
of the treatment in the kth sequence administered in the (j – 1
th) period; eijk is the within subject 
random error of Yijk. The analysis of the variance for this model has been performed on the   
ln-transformed data. Consequently, a 95% two one-sided t-test (Schuirmann) as well as a 90% shortest 
confidence interval was established. Alternatively, average bioequivalence was assessed by 
constructing an exact (1 - 2α) × 100% confidence region. 
 Mar. Drugs 2010, 8 
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4. Conclusions 
 
The formulation of metronidazole with chitosan and xanthan gum hydrophilic polymers has proven 
to be a well representative example of a sustained release solid dosage form preparation. This was 
evident in the attained prolonged in vitro drug release, in the strong bioadhesivitiy attained when tested 
on a sheep duodenum, and in the high in vivo bioavailability obtained. When compared against a 
reference commercial metronidazole drug (CMZ), results indicated the superiority of such preparation 
over the CMS in all aspects of the in vitro-in vivo analysis.  
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